Lixte Biotechnology Holdings Inc (LIXTW) News

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept...

First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...

LIXTE Biotechnology Provides Update On Recent Activities and Developments

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company...

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C...

Form 8-K - Current report